Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alpha-2a and adjusted-dose ribavirin in naive chronic hepatitis C genotype 4
NCT01686789Phase 4Completed
- Sponsor
- King Abdulaziz Medical City
- Start
- Jan 2011
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of ribavirin in hepatitis C (HCV), sponsored by King Abdulaziz Medical City. Started Jan 2011; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01686789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01686789.